{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:41:40Z","timestamp":1782967300272,"version":"3.54.5"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jtocrr.2020.100135","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T12:36:48Z","timestamp":1609245408000},"page":"100135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study"],"prefix":"10.1016","volume":"2","author":[{"given":"Nobukazu","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morihito","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Aoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuninobu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2020.100135_bib1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3109\/0284186X.2012.709948","article-title":"Treatment and survival analyses of malignant mesothelioma in Japan","volume":"52","author":"Gemba","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jtocrr.2020.100135_bib2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1349-7006.2011.02165.x","article-title":"National survey of malignant mesothelioma and asbestos exposure in Japan","volume":"103","author":"Gemba","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtocrr.2020.100135_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jjco\/hyq159","article-title":"Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan","volume":"41","author":"Nojiri","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2020.100135_bib4","unstructured":"National Comprehensive Cancer Network. NCCN guidelines version 1. 2020: Malignant pleural mesothelioma. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpm.pdf. Accessed June 15,\u00a02020."},{"key":"10.1016\/j.jtocrr.2020.100135_bib5","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2020.100135_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2020.100135_bib7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cncr.20315","article-title":"Adapting the Lung Cancer Symptom Scale\u00a0(LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation","volume":"101","author":"Hollen","year":"2004","journal-title":"Cancer"},{"issue":"suppl","key":"10.1016\/j.jtocrr.2020.100135_bib8","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/j.jtho.2018.08.275","article-title":"OA08.01 Long-term efficacy and safety of nivolumab in second- or third-line Japanese malignant pleural mesothelioma patients (phase II: MERIT study)","volume":"13","author":"Nakano","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2020.100135_bib9","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2020.100135_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial [published correction appears in Lancet Oncol. 2019;20:e132]","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2020.100135_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.21037\/atm.2017.06.26","article-title":"Malignant pleural mesothelioma: predictors and staging","volume":"5","author":"Richards","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jtocrr.2020.100135_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3816\/CLC.2010.n.005","article-title":"Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"Katirtzoglou","year":"2010","journal-title":"Clin Lung Cancer"},{"issue":"suppl","key":"10.1016\/j.jtocrr.2020.100135_bib13","doi-asserted-by":"crossref","first-page":"E42","DOI":"10.1016\/j.jtho.2020.08.004","article-title":"First-line nivolumab\u00a0+ ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743","volume":"15","author":"Baas","year":"2020","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364320301867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364320301867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:36:29Z","timestamp":1762986989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364320301867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2666364320301867"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100135","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100135"}}